Skip to main content
Ipca Laboratories Ltd. logo

Ipca Laboratories Ltd. — Investor Relations & Filings

Ticker · IPCALAB ISIN · INE571A01038 LEI · 33580069PZ8ZQVCDBC38 BSE.NS Manufacturing
Open in API
Filings indexed 724 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country IN India
Listing BSE.NS IPCALAB

About Ipca Laboratories Ltd.

https://www.ipca.com

Ipca Laboratories Ltd. is a vertically integrated entity focused on the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs) and finished dosage formulations. The company serves a global market, distributing products to over 120 countries. Its therapeutic portfolio covers rheumatology, antimalarials, cardiology, gastroenterology, pain management, and diabetology. Notably, it is a leading global producer of antimalarial agents such as Chloroquine and Hydroxychloroquine. Operations are supported by multiple manufacturing sites that adhere to international regulatory standards, alongside dedicated research and development centers. The company’s strategic emphasis on backward integration allows for optimized production processes and the delivery of high-quality medicinal solutions across diverse healthcare sectors.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 65% confidence The document is a notice filed under Regulation 30 of SEBI LODR to inform stock exchanges and the public of a scheduled conference call for Q4FY26 earnings. It contains no financial data itself and is not the earnings release nor a transcript. It is a general regulatory announcement and does not fit other specific categories, so it falls under the fallback category “Regulatory Filings.”
2026-05-21 English
Conference Call to discuss Q4FY26 Results
Regulatory Filings Classification · 85% confidence The document is an online SEBI Listing disclosure under Regulation 30(6) announcing and inviting investors and analysts to the Company's Q4 FY26 earnings conference call. It contains no financial highlights, actual earnings data, management discussion, or minutes of the call. It is not the earnings release (ER), transcript (CT), investor presentation (IP), or any detailed report. It is a standard regulatory announcement of an upcoming event and thus fits into the general Regulatory Filings fallback category (RNS).
2026-05-21 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 95% confidence The document lists names of promoters and persons acting in concert with promoters, which is typical content for a Major Shareholding Notification. There is no indication of financial data, meeting materials, or other report types. The document length is short and focused on shareholding information, fitting the Major Shareholding Notification category.
2026-04-10 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming dematerialisation activities for the quarter ended March 31, 2026. It is a compliance certificate from the Registrar and Share Transfer Agent to the company and stock exchanges. The document is short (3429 characters) and primarily serves as a regulatory compliance confirmation rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. It is not an announcement of a report but a certificate confirming regulatory compliance. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance certificates and confirmations.
2026-04-08 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding a newspaper notice about the re-lodgement transfer request of physical shares. It references compliance with SEBI regulations and includes a newspaper notice as an enclosure. The content is primarily an announcement of a corporate action related to share transfer procedures, not a financial report, earnings release, or management discussion. It does not contain financial statements, audit information, or detailed management commentary. The document is also not a proxy solicitation, voting results, or a remuneration report. Given the nature of the content as a regulatory announcement about share transfer notices and related procedural information, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-04-02 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a notification about the closure of the trading window pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. It states that the trading window will be closed from April 1, 2026, until 48 hours after the declaration of the company's audited financial results for the quarter and financial year ended March 31, 2026. The document does not contain any financial data or results itself, nor does it provide detailed financial analysis or report. It is a regulatory announcement related to insider trading compliance and timing of financial results disclosure. The document length is short (1707 characters) and it is an announcement rather than a report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-03-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.